ClinicalTrials.gg
CompletedNCT04330872ECASISUpdated Apr 2, 2020

An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.

A Phase 4 interventional study of Enteric Coated Aspirin Tablet and Plain Aspirin in Stroke, Ischemic, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-02.

Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Aug 2019, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing aspirin in Ischemic Stroke — 6 open to participants now, 6 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.

Enrollment
17th of 22
42 · median 350
Started
2019
with 1 other
Phase 4
9 of 22
2 open now
Registered
11th of 22
by date

Among the 22 studies testing aspirin in Ischemic Stroke, this one is the 17th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 4, and was the 11th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 22 studies testing aspirin in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing aspirin in Ischemic Stroke, or all of them as a file.
02

Study summary

Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.

03

Conditions studied

  • Stroke, Ischemic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed ischemic stroke who are just about to start aspirin.
  2. No prior history of cardiovascular morbidity (including ischemic heart disease, chronic kidney disease, peripheral vascular disease) 3-18- 75 years.

4-Patients with ischemic stroke who underwent reperfusion intervention (catheter-directed thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or outside the therapeutic window as the managing stroke deem fit.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant antiplatelet therapy (irrespective of the duration of the treatment).
  2. Patients on any prostaglandins related medications (non-steroidal anti-inflammatory drugs, misoprostol, and other ant secretory drugs among others).
  3. Any salicylate-containing supplements.
  4. Patients on the NG tube will be excluded from the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    Enteric coated Aspirin

    EC aspirin loading dose 300mg followed by 100 mg (2 days). The study's total duration is 3 days.

    Drug: Enteric Coated Aspirin Tablet

  • Placebo comparator
    Plain Aspirin

    Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days) The study's total duration is 3 days.

    Drug: Plain Aspirin

Interventions

  • Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).

  • DrugPlain Aspirin

    Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).

06

What researchers measure

Primary outcomes

  1. Incidence of Aspirin non-responders.

    Aspirin nonresponsiveness is defined as a level of residual serum TXB2 associated with elevated thrombotic risk (\<99.0% inhibition or TXB2 \>3.1 ng/ml) after 3 daily aspirin doses

    Time frame: At "Day 3"

Secondary outcomes

  1. Incidence of Gastrointestinal bleeding consequent upon aspirin therapy.

    Major and minor GIT bleeding

    Time frame: After three daily aspirin doses ( at "Day 3")

07

Study locations

1 site
  • Hamad Medical Corporation
    Doha, 3050, Qatar
08

References and documents

Publications

  • Elshafei MN, Imam Y, Alsaud AE, Chandra P, Parray A, Abdelmoneim MS, Obeidat K, Saeid R, Ali M, Ayadathil R, Mohamed MFH, Abdallah IM, Mohammed S, Akhtar N, Danjuma MI. The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. Eur J Clin Pharmacol. 2022 Nov;78(11):1801-1811. doi: 10.1007/s00228-022-03391-2. Epub 2022 Sep 19. PubMed 36121499 ↗
  • Elshafei MN, Imam Y, Mohamed MFH, AlSaud AE, Ahmed MS, Obeidat K, Saeid R, Ali M, Abdallah IM, Parray AS, Danjuma MI. An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). Medicine (Baltimore). 2020 May;99(20):e20307. doi: 10.1097/MD.0000000000020307. PubMed 32443379 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jan 2020, 4 months.

Of 85 phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Apr 2, 2020
StartActual
Aug 26, 2019
Primary completionActual
Jan 4, 2020
CompletionActual
Mar 4, 2020
Last update
Apr 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04330872
Responsible party
Sponsor
First posted
Apr 2, 2020
Start date
Aug 26, 2019
Primary completion
Jan 4, 2020
Completion
Mar 4, 2020
Last update
Apr 2, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion